Back to Results
First PageMeta Content



Initial Data from a Phase 2 Multiple Ascending Dose Clinical Trial of SEL-212: Monthly Dosing of SEL-212 Mitigates the Formation of Anti-Drug Antibodies and Enables Sustained Control of Serum Uric Acid in Symptomatic Gou
Add to Reading List

Document Date: 2017-12-21 11:46:23


Open Document

File Size: 560,96 KB

Share Result on Facebook